China’s SFDA Cancels Drug Maker’s License Following Investigation Of Tainted Products
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State FDA withdrew Shanghai Hualian Pharmaceutical's drug production license because the company's two leukemia drugs were found to be contaminated and caused considerable damage to patients, the drug safety watchdog announced at a Dec. 12 press conference in Beijing